Interaction Checker

Interacciones de Bendamustina

Bendamustina (Treanda, Bendeka, Belrapzo) tiene 91 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 2; moderadas: 89; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (2)

  • Alopurinolinhibidor de la xantina oxidasaGrave

    However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly. [see Warnings and Precautions (5.6) ] 5.6 Skin Reactions Fatal and serious skin reactions have been reported with bendamustine hydrochloride injection treatment in clinical trials and postmarketing safety reports, including… (etiqueta de Bendamustina, Advertencias y precauciones)

  • RituximabinmunosupresorGrave

    Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions (6.2) ] . (etiqueta de Bendamustina, Advertencias y precauciones)

Interacciones moderadas (89)

  • AbataceptinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Abrocitinibinhibidor de JAKModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • AdalimumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • AlemtuzumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • AzatioprinainmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • AzelastinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Azelastina y fluticasonaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Baricitinibinhibidor de JAKModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Bromfeniramina, pseudoefedrina y dextrometorfanoantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Cannabidiol (con receta)anticonvulsivoModerada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (etiqueta de Bendamustina, Interacciones medicamentosas)

  • CarbinoxaminaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • CetirizinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • CiclofosfamidainmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Cimetidinaantagonista H2Moderada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • CiproheptadinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • CladribinaantimetabolitoModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • ClemastinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • ClorfenaminaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Deferasiroxsuplemento de hierroModerada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • DeflazacortcorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DesloratadinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DexclorfeniraminaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DifenhidraminaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DimenhidrinatoantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DimetilfumaratoinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • DoxilaminaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Doxilamina y piridoxinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • EtanerceptinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • EverolimusinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FexofenadinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FingolimodinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • FluvoxaminaISRSModerada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • GuselkumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Hidrocodona y clorfenaminaopioideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • HidroxizinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • InfliximabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • LeflunomidainmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • LevocetirizinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Lopinavir y ritonavirantirretroviralModerada

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (etiqueta de Bendamustina, Interacciones medicamentosas)

  • LoratadinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • MeclozinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • MercaptopurinaantimetabolitoModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • MetotrexatoinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • MexiletinaantiarrítmicoModerada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • MicofenolatoinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • NatalizumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • OcrelizumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • OlopatadinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Pimecrolimusinhibidor de la calcineurinaModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • PonesimodinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • PrometazinaantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Prometazina y codeínaopioideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Ritlecitinibinhibidor de JAKModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • RitonavirantirretroviralModerada

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (etiqueta de Bendamustina, Interacciones medicamentosas)

  • SecukinumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • SirolimusinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • TeriflunomidainmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • TocilizumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • TofacitinibinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • TriamcinolonacorticosteroideModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • UpadacitinibinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • UstekinumabinmunosupresorModerada

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etiqueta de Bendamustina, Advertencias y precauciones)

  • Viloxazinainhibidor de la recaptación de noradrenalinaModerada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

  • Zileutóninhibidor de CYP1A2Moderada

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (etiqueta de Bendamustina, Interacciones medicamentosas)

Compruebe Bendamustina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.